SEC Tracker
Get the app
CMPX · XBRL financial data

Compass Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CMPX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development—year only9,52211,1748,61213,038*13,05416,41512,82613,672*13,390—
General and administrative3,0952,967*3,2484,7213,6273,536*4,9124,6512,9914,318*6,9097,403
Total operating expenses11,92615,393*12,77015,89512,23916,574*17,96621,06615,81717,990*20,29926,979
Operating income (loss)(11,926)(15,393)*(12,770)(15,045)(12,239)(16,574)*(17,966)(21,066)(15,817)(17,990)*(20,299)(26,979)
Interest income1,9621,978*2,0002,0001,8001,600*1,3001,200—year only——
Other income (expense)1,9621,978*1,9831,9691,7581,541*1,3331,1851,5582,274*1,9821,825
Income tax expense (benefit)00*00—year only0——year only——
Net income (loss)(9,964)(13,415)*(10,787)(13,076)(10,481)(15,033)*(16,633)(19,881)(14,259)(15,716)*(18,317)(25,154)
Earnings per share, basic USD per share(0.08)(0.11)*(0.08)(0.10)(0.08)(0.11)*(0.12)(0.14)(0.08)(0.09)*(0.10)(0.13)
Weighted average shares, basic thousands of shares127,424127,563*136,608137,589137,589137,744*138,236138,282168,782184,846*186,400186,798
Weighted average shares, diluted thousands of shares————137,600—138,200—————

Balance sheet

CSV

Fiscal quarters (CMPX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents30,42624,22823,67419,40436,80143,48341,04822,85646,21230,64355,16835,453
Marketable securities133,277128,233132,581126,82398,60183,23971,58778,093173,683178,263139,519144,426
Prepaid and other current assets2,8811,4202,3567,3195,7386,02911,5105,2461,2259131,0001,011
Total current assets166,584153,881158,611153,546141,140132,751124,145106,195221,120209,819195,687180,890
Property and equipment, net1,051898744592493353231131119102169324
Right-of-use asset2,0831,7761,4671,1536,9506,7316,5079,8049,4529,0998,7468,391
Total assets170,038156,875161,142155,611149,151140,403131,451116,698231,259219,588205,170190,173
Accounts payable2,3064,0908541,1929602,2491,5772,5953,0951,5859062,906
Accrued liabilities5,6442,5141,8157,2272,9166,28713,21410,9928,68411,3838,00011,585
Total current liabilities9,1247,8013,8939,5074,4338,87414,90013,85812,41213,96810,27916,128
Lease liability, non-current86953618906,3206,2966,2729,6339,2348,8298,4187,996
Total liabilities9,9938,3374,0829,50710,75315,17021,17223,49121,64622,79718,69724,124
Accumulated deficit(301,893)(315,308)(326,095)(339,171)(349,652)(364,683)(381,316)(401,197)(415,456)(431,172)(449,489)(474,643)
Total stockholders' equity160,045148,538157,060146,104138,398125,233110,27993,207209,613196,791186,473166,049
Total liabilities and equity170,038156,875161,142155,611149,151140,403131,451116,698231,259219,588205,170190,173
Common shares outstanding (cover page) thousands of shares127,486137,589137,589137,589137,589138,282138,282138,282177,862180,088180,088180,088

Cash flows

CSV

Fiscal quarters (CMPX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(9,964)(13,415)*(10,787)(13,076)(10,481)(15,033)*(16,633)(19,881)(14,259)(15,716)*(18,317)(25,154)
Stock-based compensation1,625*1,600*2,0032,121*2,198*2,238*2,5142,791*1,238*1,825*5,0734,822*
Net cash from operating activities(5,922)*(12,354)*(13,888)(10,754)*(11,051)*(9,162)*(13,208)(11,832)*(10,849)*(13,254)*(17,269)(14,738)*
Purchases of property and equipment10*9*00*44*0*180*7*0*82176*
Net cash from investing activities17,049*6,314*(4,099)6,483*29,018*15,370*11,588(6,360)*(95,156)*(3,378)*38,429(4,977)*
Proceeds from issuing common stock0*0*18,1130*0*0*00*137,999*0*——
Proceeds from issuing equity———0*0*——0*138,000*——0*
Net cash from financing activities21*(158)*17,4331*(2)*(94)*(815)0*129,361*1,063*3,3650*
Net change in cash11,148*(6,198)*(554)(4,270)*17,965*6,114*(2,435)(18,192)*23,356*(15,569)*24,525(19,715)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Compass Therapeutics35,453not reported(14,738)*180.1M12.2 quarters 10-QJun 30, 2026
Ocugen24,6321,951(15,739)*339.3M5.1 quarters 10-QSep 30, 2026
Abeona Therapeutics56,22911,380(17,496)*57.2M8.4 quarters 10-QJun 30, 2026
Tonix Pharmaceuticals Holding176,23213,544(42,243)*17.2M4.2 quarters 10-QJun 30, 2026
Vanda Pharmaceuticals61,93369,815(28,435)*60.5M1.7 quarters 10-QSep 30, 2026
Standard Biotools267,48719,385(6,161)*394.8M21.6 quarters 10-QSep 30, 2026
Aquestive Therapeutics90,3497,557(7,046)*125.7M8.4 quarters 10-QSep 30, 2026
Atea Pharmaceuticals76,548not reported(37,084)*80.2M5.9 quarters 10-QJun 30, 2026
Siga Technologies117,58441,00215,174*71.8M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.